New York, December 31 The Coverna-19 vaccine of the American company of Modern Biotechnology has demonstrated 94.1% effectiveness, showed results from …
New York, December 31 The Covid-19 vaccine of the American company of Modern Biotechnology demonstrated the effectiveness of 94.1%, showed the results of the primary analysis of a phase 3 study.
The study, published in The New England Journal of Medicine, provides evidence that the vaccine, mRNA-1273, can prevent symptomatic infection.
The results are similar to the first interim analysis of the study announced by Moderna in November, which demonstrated the vaccine’s effectiveness of 94.5%.
The new paper published Wednesday said that of the more than 30,000 participants randomized to receive the vaccine or a placebo, 11 of those in the vaccine group developed symptomatic Covid-19, compared with 185 participants who received placebo, demonstrating 94.1 % efficacy in preventing symptomatic COVID-19.
Cases of severe Covid-19 occurred only in participants who received placebo.
“Our work continues. In the coming months, we will have increasing amounts of data to better define how this vaccine works, but the results so far show an effectiveness of 94.1%. These figures are convincing,” he said. said Lindsey Baden, an infectious disease. specialist at Brigham and Women’s Hospital in the USA.
And, importantly, the data suggest protection against severe disease, indicating that the vaccine could have an impact on the prevention of hospitalizations and deaths, at least in the first few months after vaccination.
The study enrolled 30,420 adults participating in 99 sites in the United States, including more than 600 participants enrolled in Brigham.
Eligible participants were 18 years of age or older with no known history of SARS-CoV-2 infection and whose locations or circumstances put them at significant risk of SARS-CoV-2 infection and / or high risk of severe Covid-19.
Participants received the first injection between July 27 and October 23, 2020, followed by a second injection 28 days later.
In the placebo group, 185 participants developed symptomatic Covid-19 disease; In the vaccine group, 11 participants did so.
Thirty participants had severe Covid-19, all from the placebo group, the study said.
In general, reactions to the vaccine were mild, with about half of the patients experiencing fatigue, muscle aches, joint pain and headaches, all the more so after the second dose, she added.
“Although these results are encouraging, they are limited by the short follow-up time so far. Longer-term data from the current study may allow us to more closely assess the effectiveness of the vaccine between different groups, determine the impact on asymptomatic infection, understand when immunity decreases and determine whether vaccines affect infectivity, “Baden said.
(With IANS entries)
Disclaimer: This post was automatically published from an agency feed with no text changes and was not reviewed by an editor.